PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology is a biopharmaceutical company that develops and commercializes cancer treatments. Its commercial product is NERLYNX, an oral form of neratinib approved in the United States for certain early-stage and advanced or metastatic HER2-positive breast cancers. Puma markets NERLYNX in the United States through a direct specialty sales force and works with sublicensees to pursue approval and commercialization in countries outside the United States. Puma also holds worldwide research, development and commercial rights to alisertib, an investigational drug candidate designed to inhibit Aurora Kinase A. The company intends to pursue its development initially for small cell lung cancer and hormone receptor-positive breast cancer. Puma makes money by commercializing NERLYNX and, through its sublicense agreements, authorizes third parties to commercialize the product in certain regions. Puma is headquartered in Los Angeles, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PBYI in the last 30 days.
See all $PBYI insider activity →Puma Biotechnology (PBYI) reported Q3 earnings, noting declines in patient enrollments and commercial new patient starts. China royalty adjustments reduced revenue, leading to revised full-year guidance: royalties $18M-$19M (down from $20M-$23M) and net NERLYNX product revenue $205M-$208M. Net income forecast raised to $20M-$22M. The company updated clinical trial progress for alisertib and remains debt-free.
Puma Biotech (PBYI) reported Q3 earnings of $0.15 per share, exceeding estimates by $0.04. Revenue was $55.1M, missing estimates by 3.54%. The company has beaten EPS estimates four times in the last year. Shares are up 79.7% YTD. Future performance depends on earnings outlook and management commentary.
Puma Biotechnology reported Q3 Non-GAAP EPS of $0.15 and revenue of $55.1M, up 1.1% year-over-year. Operating cash flow increased to $14.6M from $9.7M in the same period last year, according to the company.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning PBYI (PUMA BIOTECHNOLOGY, INC.). Coverage has skewed bullish: 4 bullish, 3 neutral, and 0 bearish.
Recent PBYI coverage spans earnings, market movers and insider activity.
Guidance reduction on royalties and product revenue suggests near-term pressure, while raised net income forecast offers upside.
Earnings beat on EPS may drive short-term buying pressure despite revenue miss.
Modest earnings likely keep the stock flat or cause slight downside pressure.
Raised guidance suggests improved earnings outlook.
Positive catalyst from new trial data and drug licensing could boost near‑term demand.
AlphAI scores every news story that mentions PBYI with an AI model for sentiment and relevance, and aggregates insider trades from PUMA BIOTECHNOLOGY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Puma Biotechnology (PBYI) reported Q3 earnings, noting declines in patient enrollments and commercial new patient starts. China royalty adjustments reduced revenue, leading to revised full-year guidance: royalties $18M-$19M (down from $20M-$23M) and net NERLYNX product revenue $205M-$208M. Net income forecast raised to $20M-$22M. The company updated clinical trial progress for alisertib and remains debt-free.
Puma Biotech (PBYI) reported Q3 earnings of $0.15 per share, exceeding estimates by $0.04. Revenue was $55.1M, missing estimates by 3.54%. The company has beaten EPS estimates four times in the last year. Shares are up 79.7% YTD. Future performance depends on earnings outlook and management commentary.
Puma Biotechnology reported Q3 Non-GAAP EPS of $0.15 and revenue of $55.1M, up 1.1% year-over-year. Operating cash flow increased to $14.6M from $9.7M in the same period last year, according to the company.
PUMA BIOTECHNOLOGY, INC. (PBYI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Puma Biotechnology Reports Third Quarter 2026 Financial Results - Third quarter U.S. NERLYNX sales driven by increased year-over-year demand - Raising 2026 net income guidance LOS ANGELES, Calif., Nov. 5, 2026 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a
Several biotech stocks reached 52-week highs on October 9, 2026. Humana (HUM) rose 11% to $456.50, driven by improved Medicare Advantage ratings. Puma Biotechnology (PBYI) gained 3% to $10.10, while AbbVie (ABBV) hit $274.94. Moderna (MRNA) surged 14% to $225 after positive clinical trial results. AVITA Medical (RCEL) climbed to $13.71, reporting 18% revenue growth in Q2 2026.
On September 30, 2026, biotech stocks PGEN, EXEL, TWST, HNGE, and PBYI hit 52-week highs. PGEN rose 6% to $9.98, EXEL reached $61.14, TWST climbed 3% to $197.19, HNGE hit $98.41, and PBYI touched $10.10. Key catalysts included clinical trial results, FDA designations, and revenue growth.
Cesano Alessandra sold 62,150 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $9.12 ($0.57M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
Puma Biotechnology (PBYI) reported Q2 2026 revenue of $56.5 million, up from $52.4 million a year earlier, driven by NERLYNX net product revenue of $53.6 million. GAAP net income was $8.2 million ($0.16/share). The company raised full-year net product revenue guidance to $205 million to $209 million and net income to $17 million to $20 million, while lowering royalty guidance to $19 million to $22 million.
Puma Biotechnology (PBYI) reported Q2 earnings call updates. It is advancing Phase II alisertib trials ALISCA-Breast1 and ALISCA-Lung1, amending ALISCA-Breast1 to enroll only 40 mg and 50 mg twice daily, and continuing ALISCA-Lung1 enrollment at 70 mg twice daily. 2026 guidance: net NERLYNX revenue $205M-$209M, net income $17M-$20M. Q3 net NERLYNX $54M-$56M; cash about $93.9M; debt-free.
PUMA BIOTECHNOLOGY, INC. (PBYI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter 2026 Financial Results Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES, Calif., Aug. 6, 2026 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
